“Down regulation” of 5-HT₂ receptors: Possible role of melatonin and significance for negative Schizophrenia

References

• Aghujanian G. K., Haigler H. J. Mode of action of LSD on serotonergic neurons. Advances in Biochemical Psychopharmacology 1974; 10: 167–176
   PubMedGoogle Scholar
• Bar-Or A., Brown G. M. Pineal involvement in the diurnal rhythm of nociception in the rat. Life Sciences 1989; 44: 1067–1075
   PubMed Web of Science ®Google Scholar
• Bennett J. P., Enna S. J., Bylund D. B. Neurotransmitter receptors in frontal cortex of schizophrenics. Archives of General Psychiatry 1979; 36: 927–934
   PubMed Web of Science ®Google Scholar
• Bleich A., Brown S. L., Kahn R., Van Praag H. M. The role of serotonin in schizophrenia. Schizophrenia Bulletin 1988; 14: 297–315
   PubMedGoogle Scholar
• Brambilla F., Facchinetti F., Petraglia F., Vanzulli L., Genazzani A. R. Secretion pattern of endogenous opioids in chronic schizophrenia. American Journal of Psychiatry 1984; 141: 1183–1189
   PubMedGoogle Scholar
• Bruinink A., Lichtensteiger W., Schlumpf M. Pre- and post-natal ontogeny and characterization of dopaminergic D2, serotonergic S2, and spirodecanone binding sites in rat forebrain. Journal of Neurochemistry 1983; 40: 1227–1232
   PubMed Web of Science ®Google Scholar
• Cculcmans D. L. S., Gelder S. Y. G., Hoppenbrouwers M. L. J. A., Reyntjens A. J. M., Janssen P. A. J. Effect of serotonin antagonism in schizophrenia: A pilot study with sctopcrone. Psycho-pharmacology 1985; 85: 329–332
   PubMedGoogle Scholar
• Crews F. T., Scott J. A., Shorstein N. H. Rapid down-regulation of serotonin2 receptor binding during combined administration of tricyclic antidepressant drugs and alpha2 antagonists. Neuropharmacology 1983; 22: 1203–1209
   PubMedGoogle Scholar
• Dugovic C, Leysen J. E., Wauqier A. Melatonin modulates the sensitivity of 5-hydroxytryptamine-2-receptor-mediated sleep-wakefullness regulation in the rat. Neuroscience Letters 1989; 104: 320–325
   PubMed Web of Science ®Google Scholar
• Gaffori O., Van Ree J. M. Serotonin and antidepressant drugs antagonize melatonin-induced behavioural changes after injection into the nucleus accumbens of rats. Psychopharmacology 1985; 24: 237–244
   Google Scholar
• Gelders Y., Vanden Bussche G., Reyntjens A., Janssen P. Serotonin-S2 receptor blockers in the treatment of chronic schizophrenia. Clinical Neuropharmacology 1986; 9: 325–327, (Suppl)
   Web of Science ®Google Scholar
• Green A. R., Heal D. J. The effects of drugs on serotonin-mediated behavioural models. Neuropharmacology of serotonin, A.R. Green. Oxford University Press, p. 344, Oxford 1985
   Google Scholar
• Hanssen T., Wetterberg L. Serum levels of melatonin in schizophrenic patients. A possible indicator of beta-adrenergic function and of responsiveness to beta-adrenergic blocking drugs (propranolol). Neuroendocrinology Letters 1983; 5: 413–417
   Google Scholar
• Idzikowski C, Mills F. J., Glennard R. 5-hydroxytryptamine-2-antagonist increases human slow wave sleep. Brain Research 1986; 378: 164–168
   PubMed Web of Science ®Google Scholar
• Kane J. M., Honigfeld G., Singer J., Meltzer H. Y. (9188). Clozapine to the treatment resistant schizophrenic: a double blind comparison versus chlorpromazine/ benztropine. Archives of General Psychiatry, 45: 789–796, Clozaril Collabortative Study Group
   PubMedGoogle Scholar
• Kavaliers M., Hirst M., Teskey G. C. Ageing, opioid analgesia and the pineal gland. Life Sciences 1983; 32: 2279–2287
   PubMed Web of Science ®Google Scholar
• King R., Faull K. F., Stahl S. M., Mefford I. N., Thiemann S., Barchas J. D., Berger P. A. Serotonin and schizophrenia: Correlations between serotonergic activity and schizophrenic motor behavior. Psychiatry Research 1985; 14: 235–240
   PubMed Web of Science ®Google Scholar
• Lakin M. L., Miller C. H., Stott M. L., Winters W. D. Involvement of the pineal gland and melatonin in murine analgesia. Life Sciences 1981; 29: 2543–2551
   PubMed Web of Science ®Google Scholar
• Lee T., Tang S. W. Loxapine and clozapine decreases serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Research 1984; 12: 277–285
   PubMedGoogle Scholar
• Leysen J. Serotonin receptor binding sites: Is there pharmacological and clinical significance. Medical Biology 1983; 61: 139–143
   PubMedGoogle Scholar
• Leysen J. E., Gommeren W., Van Gompel P., Wynants J., Janssen P., Laduron P. M. Receptor binding properties in vitro and in vivo of ritanserin: a very potent and long-acting serotonin 5-HT2 antagonist. Molecular Pharmacology 1985; 27: 600–611
   PubMed Web of Science ®Google Scholar
• Leysen J. E., Van Gompel P., Gommeren W., Woestenborghs R., Janssen P. A. J. Down-regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with serotonin-S2 antagonists: Ritanserin and setoperone. Psychopharmacology 1986; 88: 434–444
   PubMed Web of Science ®Google Scholar
• Lindstrom L. H. The effect of long term treatment with clozapine in schizophrenia: A retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatrica Scandinavica 1988; 77: 524–529
   PubMed Web of Science ®Google Scholar
• Lissoni P., Esposti D., Esposti G., Mauri R., Resentini M., Morabito F., Fumagali P., Santagostino A., Delitala G., Fraschini F. A clinical study on the relationship between the pineal gland and the opioid system. Journal of Neural Transmission 1986; 65: 63–73
   PubMed Web of Science ®Google Scholar
• MacKay A. V. P. Positive and negative schizphrenic symptoms and the role of dopamine: Discussion I. British Journal of Psychiatry 1980; 137: 379–383
   PubMed Web of Science ®Google Scholar
• Maertens de Noordhout A., Delwaide P. J. Open pilot trial of ritanserin in parkinsonism. Clinical Neuropharmacology 1986; 9: 480–484
   PubMed Web of Science ®Google Scholar
• Maloteaux J. M., Laterre E.C., Laduron P. M. Decrease of serotonin-S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy. Movement Disorders 1988; 3: 255–262
   PubMedGoogle Scholar
• Miles A., Philbrick D. R. S. Melatonin and Psychiatry. Biological Psychiatry 1988; 23: 405–425
   PubMed Web of Science ®Google Scholar
• Mita T., Hanada S., Nishino N. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biological Psychiatry 1986; 21: 1407–1414
   PubMed Web of Science ®Google Scholar
• Peroutka S. J., Snyder S. H. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 1980; 210: 88–90
   PubMed Web of Science ®Google Scholar
• Peroutka S. J., Lebovitz R. M., Snyder S. H. Two distinct central serotonin receptors with distinct physiological functions. Science 1981; 212: 827–829
   PubMed Web of Science ®Google Scholar
• Peroutka S. J., Snyder S. H. Multiple serotonin receptors and their physiological significance. Federation Proceedings 1983; 42: 213–217
   PubMedGoogle Scholar
• Resnick O., Krus D. M., Ruskin M. LSD-25 action in normal subjects treated with a monoamine oxidase inhibitor. Life Sciences 1964; 3: 1207–1214
   Web of Science ®Google Scholar
• Reynolds G. P., Rossor M. N., Iversen L. L. Preliminary studies of human cortical 5-HT, receptors and their involvement in schizophrenia and neuroleptic drug action. Journal of Neural Transmission 1983; 18: 273–277, (suppl)
   Google Scholar
• Souetre E., Salvati E., Belugou J. L., Robert P., Brunet G., Darcourt G. Antidepressant effect of 5-methyoxypsoralen: A preliminary report. Psychopharmacology 1988; 95: 430–431
   PubMed Web of Science ®Google Scholar
• Ugedo L., Grenhoff J., Svensson TH. Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 1989; 98: 45–50
   PubMed Web of Science ®Google Scholar
• Van Kammen D. P., Van Kammen W. B., Mann L. S., Seppala T., Linnoila M. Dopamine metabolism in the cerebrospinal fluid of drug free schizophrenic patients with and without cortical atrophy. Archives of General Psychiatry 1986; 43: 978–983
   PubMed Web of Science ®Google Scholar
• Wendel O. T., Waterbury L. D., Pearce L. A. Increase in monoamine concentration in rat brain following melatonin administration. Experientia 1974; 30: 1167–1168
   PubMedGoogle Scholar
• Wilmot C. A., Szczepanik A. M. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Research 1989; 487: 288–298
   PubMedGoogle Scholar
• Zisapel N., Egozi Y., Laudon M. Inhibition of dopamine release by melatonin: regional distribution in the rat brain. Brain Research 1983; 246: 161–163
   Google Scholar